国内臨床試験では、どのような患者にトルリシティ（デュラグルチド）を投与したのか？

［解説］

トルリシティの有効性が示された国内第3相臨床試験（GBDP、GBDY及びGBDQ試験）の患者背景は、平均年齢約53～59歳、平均罹病期間約6～9年、平均HbA1c約8.1～8.9%でした。詳細は各試験の論文をご参照ください^1-4。

［引用元］

1. Miyagawa J et al. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes, Obesity and Metabolism 2015; 17(10):974-983

2. Odawara M et al. Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in J apanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study. Diabetes, Obesity and Metabolism 2016; 18(3):249-257

3. Araki E et al. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. Diabetes, Obesity and Metabolism 2015; 17(10):994-1002

4. Emoto M et al. A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial. Endocrine Journal 2015; 62(12):1101-1114